Hodgkin Lymphoma (HL) Treatment and Our Challenges in Bangladesh
Keywords:Hodgkin Lymphoma, Challenges in Bangladesh
Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012; 30:2183-2189
Chen, R. et al. Keynote. phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J. Clin. Oncol. 35, 2125–2132 (2017).
Diefenbach CS, Hong F, Ambinder RF et al. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. Lancet Haematol. 2020; 7(9):E660-E670
Ramos CA, Bilgi M, Gerken C, et al. CD30-chimeric antigen receptor (CAR) T cells for therapy of Hodgkin lymphoma (HL). Abstract #79. Presented at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR, February 23, 2019; Houston, TX.
Grover NS, Park SI, Ivanova A, et al. A phase Ib/II study of anti-CD30 chimeric antigen receptor T cells for relapsed/refractory CD30+ lymphomas. Abstract #83. Presented at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR, February 23, 2019; Houston, TX.
Straus, D. J. et al. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood 135, 735–742 (2020).
Ramchandren R, Fanale MA, Rueda A, et al. Nivolumab for Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study. ASH 2017. Abstract 651.1.
Brockelman et al. Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma -The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial JAMA Oncol. 2020;6(6):872-880.
Moskowitz, C. H. et al. from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood 132, 2639–2642 (2018)
How to Cite
Copyright (c) 2021 Abu Jafar Mohammed Saleh
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The users are allowed to read, download, copy, or redistribute this article in any medium or format, without asking prior permission from the publisher or the author for non-commercial use, provided the original work is properly cited.